[1]梁 艳,张学良,白晓蓉,等.血清MCP-1、CXCL16与乳腺癌新辅助化疗效果和预后关系研究[J].陕西医学杂志,2025,54(5):645-648.[doi:DOI:10.3969/j.issn.1000-7377.2025.05.014]
　LIANG Yan,ZHANG Xueliang,BAI Xiaorong,et al.Relationship between serum MCP-1,CXCL16 and the efficacy of neoadjuvant chemotherapy and prognosis in breast cancer[J].,2025,54(5):645-648.[doi:DOI:10.3969/j.issn.1000-7377.2025.05.014]
点击复制

血清MCP-1、CXCL16与乳腺癌新辅助化疗效果和预后关系研究
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
54
期数:
2025年5期
页码:
645-648
栏目:
临床研究
出版日期:
2025-05-05

文章信息/Info

Title:
Relationship between serum MCP-1,CXCL16 and the efficacy of neoadjuvant chemotherapy and prognosis in breast cancer
作者:
梁 艳1; 张学良2; 白晓蓉1; 高 晨1; 董成芳1
(1.甘肃省肿瘤医院乳腺外科,甘肃 兰州 730000; 2.甘肃省肿瘤医院肿瘤内科,甘肃 兰州 730000)
Author(s):
LIANG Yan1; ZHANG Xueliang2; BAI Xiaorong1; GAO Chen1; DONG Chengfang1
(1.Department of Breast Surgery,Gansu Provincial Cancer Hospital,Lanzhou 730000,China; 2.Department of Medical Oncology,Gansu Provincial Cancer Hospital,Lanzhou 730000,China)
关键词:
乳腺癌;  单核细胞趋化蛋白-1;  CXC趋化因子配体16;  新辅助化疗;  预后;  预测价值
Keywords:
Breast cancer;  Monocyte chemoattractant protein-1;  CXC chemokine ligand 16;  Neoadjuvant chemotherapy;  Prognosis;  Predictive value
分类号:
R 737.9
DOI:
DOI:10.3969/j.issn.1000-7377.2025.05.014
文献标志码:
A
摘要:
目的:探讨血清单核细胞趋化蛋白-1(MCP-1)、CXC趋化因子配体16(CXCL16)与乳腺癌新辅助化疗(NAC)效果和预后的关系。方法:选取乳腺癌患者125例,给予手术前NAC治疗,根据NAC疗效将患者分为病理完全缓解(pCR)组(31例)和非pCR组(94例)。术后随访5年,根据预后情况分为预后不良组(27例)和预后良好组(98例)。比较不同NAC疗效及预后患者血清MCP-1、CXCL16水平。采用Spearman法分析血清MCP-1、CXCL16水平与患者NAC疗效及预后的相关性。绘制受试者工作特征(ROC)曲线分析血清MCP-1、CXCL16对乳腺癌患者NAC疗效以及预后不良的预测价值。结果:非pCR组血清MCP-1、CXCL16水平高于pCR组(均P<0.05)。预后不良组血清MCP-1、CXCL16水平高于预后良好组(均P<0.05)。血清MCP-1、CXCL16水平与非pCR呈正相关,与预后不良呈正相关(均P<0.05)。血清MCP-1、CXCL16及两者联合预测乳腺癌患者NAC治疗后非pCR的曲线下面积(AUC)分别为0.824、0.842、0.942,且两者联合预测的AUC大于血清MCP-1、CXCL16单独预测的AUC(均P<0.05)。血清MCP-1、CXCL16及两者联合预测乳腺癌患者预后不良的AUC分别为0.710、0.779、0.864,且两者联合预测的AUC大于血清MCP-1单独预测的AUC(均P<0.05)。结论:血清MCP-1、CXCL16与乳腺癌NAC疗效和预后有关,且两者对患者NAC疗效及预后不良具有较高的预测价值。
Abstract:
Objective:To investigate the relationship between serum monocyte chemoattractant protein-1(MCP-1),CXC chemokine ligand 16(CXCL16)and the efficacy of neoadjuvant chemotherapy(NAC)as well as prognosis in breast cancer.Methods:A total of 125 patients with breast cancer who received NAC before surgery were included.Patients were divided into the pathological complete response(pCR)group(31 cases)and non-pCR group(94 cases)based on the efficacy of NAC.After surgery,patients were followed up for 5 years and further divided into poor-prognosis group(27 cases)and good-prognosis group(98 cases)based on their prognosis.Serum levels of MCP-1 and CXCL16 were compared between different NAC efficacy and prognosis groups.Spearman correlation analysis was used to assess the correlation between serum MCP-1 and CXCL16 levels with NAC efficacy and prognosis.Receiver operating characteristic(ROC)curves were plotted to analyze the predictive value of serum MCP-1 and CXCL16 for NAC efficacy and poor prognosis in breast cancer patients.Results:Serum levels of MCP-1 and CXCL16 were higher in the non-pCR group compared to the pCR group(all P<0.05).Similarly,patients in the poor-prognosis group had higher serum levels of MCP-1 and CXCL16 compared to those in the good-prognosis group(all P<0.05).Serum MCP-1 and CXCL16 levels were positively correlated with non-pCR and poor prognosis(all P<0.05).The AUC for predicting non-pCR in breast cancer patients using serum MCP-1,CXCL16 and the combination of both were 0.824,0.842 and 0.942,respectively.The combined prediction had a higher AUC than individual predictors(all P<0.05).For predicting poor prognosis,the AUC values for serum MCP-1,CXCL16 and the combination were 0.710,0.779,and 0.864,respectively,with the combined prediction showing a higher AUC than serum MCP-1 alone(all P<0.05).Conclusion:Serum MCP-1 and CXCL16 levels are associated with the efficacy of NAC and prognosis in breast cancer patients,and both markers have high predictive value for the efficacy of NAC and poor prognosis.

参考文献/References:

[1] 吴娟,孙圣荣,袁静萍.肿瘤微环境与乳腺癌[J].中国组织化学与细胞化学杂志,2018,27(1):82-86.
[2] 冀峰,吕复君,李延翠.hMAM mRNA表达情况与乳腺癌的关系[J].癌症进展,2018,16(3):315-317.
[3] 姜来,张钧,詹亚惠,等.血清BRCA1、BRCA2、MCP-1及MMP-9水平在乳腺癌早期预测中的作用[J].中国妇幼保健,2024,39:2570-2573.
[4] ROGERS C,LLOREN J I,JOHNSON M K,et al.National trends in neoadjuvant chemotherapy utilization for cT1-2 N0 triple negative breast cancer:Did the CREATE-X trial impact treatment patterns?[J].J Clin Oncol,2023,41(16_suppl):e12599.
[5] 郭树鹏,栾莉莉,崔志馨,等.青葙苷A抑制缺氧乳腺癌MDA-MB-231细胞增殖、迁移和侵袭能力的研究[J].辽宁中医药大学学报,2023,25(12):30-35.
[6] XIANG H,XIN L,YE J,et al.A multicenter study on efficacy of dual-target neoadjuvant therapy for HER2-positive breast cancer and a consistent analysis of efficacy evaluation of neoadjuvant therapy by Miller-Payne and RCB pathological evaluation systems(CSBrS-026)[J].Chin J Cancer Res,2023,35(6):702-712.
[7] 张良,崔巍.CXC趋化因子在乳腺癌中的作用研究进展[J].浙江医学,2024,46(15):1663-1666.
[8] 周永安,阮勇.白蛋白结合型紫杉醇与多西紫杉醇在人表皮生长因子受体-2阳性乳腺癌患者新辅助化疗中的疗效对比研究[J].陕西医学杂志,2024,53(9):1236-1239,1244.
[9] 李丹云,蓝婉宁,袁泽焕,等.乳腺癌-抑郁症关联基因筛选与中药预测的生物信息学研究[J].广西医学,2023,45(15):1856-1863.
[10] 中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2019年版)[J].中国癌症杂志,2019,29(8):609-679.
[11] VERDIAL F C,MAMTANI A,PAWLOSKI K R,et al.The effect of age on outcomes after neoadjuvant chemotherapy for breast cancer[J].Ann Surg Oncol,2022,29(6):3810-3819.
[12] 王影,周明俊,朱倩文,等.HIF-1α活化介导的胆固醇稳态失调加速大鼠的糖尿病肾病进展[J].南方医科大学学报,2023,43(10):1782-1788.
[13] 王玉龙,张美荣,周昱.乳腺癌患者血清微小RNA-135b、微小RNA-148a-3p、微小RNA-186-5p表达水平及其与新辅助化疗效果相关性研究[J].陕西医学杂志,2024,53(5):684-687,691.
[14] 蔡蓉蓉,施平平,顾春燕.高迁移率族蛋白B1巨噬细胞转移抑制因子联合CXC亚家族趋化因子16对高危型HPV感染患者诊断价值[J].河北医学,2024,30(7):1160-1165.
[15] 郭莉,马瑞风,董玉.CXCL10、LPA蛋白在卵巢癌组织中的表达及与预后的关系[J].临床误诊误治,2023,36(8):80-83.
[16] POGGIO F,TAGLIAMENTO M,CEPPI M,et al.Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer:The end of the debate[J].Ann Oncol,2022,33(3):347-349.
[17] 刘小娜,郝娜,马晓霞,等.三黄煎剂联合吡柔比星、多西他赛、环磷酰胺新辅助化疗治疗三阴乳腺癌临床研究[J].陕西中医,2021,42(10):1367-1370.
[18] LI Z,XIAO H,LI J,et al.Graphene oxide-based highly sensitive assay of circulating microRNAs for early prediction of the response to neoadjuvant chemotherapy in breast cancer[J].Anal Chem,2022,94(46):16254-16264.
[19] 刘旭鹏,卢燕琼,韦文念.血清HMGA1、CXCL16水平与宫颈癌患者HPV感染分型的相关性分析[J].临床和实验医学杂志,2023,22(14):1526-1529.
[20] 徐龙飞,韩晶,杨喆,等.LRG1抑制小鼠肝巨噬细胞活化从而改善代谢相关脂肪性肝病:基于增强TGF-β1信号通路[J].南方医科大学学报,2023,43(7):1164-1171.
[21] GAO W,AN A,YANG L,et al.Neoadjuvant chemotherapy for male breast cancer:A case report[J].Asian J Surg,2024,47(8):3730-3731.
[22] 赵琴.通痹活络汤联合依达拉奉对急性脑梗死患者血清CXCL-16、MCP-1和GDF-15的影响[J].西部中医药,2022,35(1):16-20.
[23] 王成,王晓玲,汪旻琦,等.女贞莲桂白芍汤联合常规辅助化疗治疗三阴性乳腺癌术后疗效研究[J].陕西中医,2023,44(12):1735-1739.
[24] 李佳熹,曹炬.趋化因子CXCL16对脓毒症小鼠生存率、组织损伤及炎症反应的影响[J].中国免疫学杂志,2022,38(9):1037-1041,1046.
[25] 陈奇,柏晶晶,谢小东,等.山豆根多糖通过JAK-STAT/NF-κB信号通路干预PCV2感染免疫细胞炎性反应及免疫抑制的研究[J].饲料研究,2023,46(23):67-73.

相似文献/References:

[1]乔亚舜,吴瑛琦.乳腔镜腋窝淋巴结清扫术治疗早期乳腺癌临床研究[J].陕西医学杂志,2019,(4):473.
　QIAO Yashun,WU Yingqi..Clinical study of mammoscopic axillary lymph node dissection for early breast cancer patients[J].,2019,(5):473.
[2]谭兴利,陆伟辉,汤学文,等.乳腺癌患者超声检查中PSV、RI值与术后组织中MMP11、VEGF表达的相关性探讨[J].陕西医学杂志,2019,(5):617.
[3]韩丕华,宋张骏△,杨晓民,等.乳腺超声造影联合细针穿刺定位活检在判定乳腺癌新辅助化疗后腋窝淋巴结性质中的临床研究*[J].陕西医学杂志,2019,(7):842.
　HAN Pihua,SONG Zhangjun,YANG Xiaomin,et al.Application of breast contrast-enhanced ultrasonography combined with fine needle aspiration biopsy in determining the axillary lymph node properties after neoadjuvant chemotherapy for breast cancer[J].,2019,(5):842.
[4]蒋 敢,王 军,王会东△.舒芬太尼联合罗哌卡因肋间神经阻滞对乳腺癌患者术后镇痛、免疫功能及应激反应的影响*[J].陕西医学杂志,2019,(8):1077.
　JIANG Gan,WANG Jun,WANG Huidong..Effect of sufentanil plus ropivacaine intercostal nerve block on postoperative analgesia, immunity and stress response in patients with breast cancer[J].,2019,(5):1077.
[5]王群拴,黎小花△.核磁共振结合血清肿瘤标志物及细胞因子检测在〖JZ〗乳腺癌诊断中的应用价值研究*[J].陕西医学杂志,2019,(10):1295.
[6]韩丕华,袁 权△.乳腺癌患者白细胞介素-22表达水平对新辅助化疗后病理学完全缓解的预测价值*[J].陕西医学杂志,2020,49(7):889.[doi:DOI:10.3969/j.issn.10007377.2020.07.033]
　HAN Pihua,YUAN Quan..Predictive value of IL-22 expression level in breast cancer patients for pathological complete remission after neoadjuvant chemotherapy[J].,2020,49(5):889.[doi:DOI:10.3969/j.issn.10007377.2020.07.033]
[7]汪雅琴,李 伟,邵 杰.桉柠蒎联合气管镜下灌洗治疗肺脓肿临床研究[J].陕西医学杂志,2021,50(1):55.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.014]
[8]韩金怡,苏志勇.21基因检测对早期Luminal A型乳腺癌治疗指导作用研究[J].陕西医学杂志,2021,50(9):1081.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.010]
　HAN Jinyi,SU Zhiyong.Guiding role of 21-gene detection in treatment of early Luminal type A breast cancer[J].,2021,50(5):1081.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.010]
[9]白玲娇,陈小军,王 婷.乳腺癌超声弹性成像评分与免疫组化指标表达水平相关性分析[J].陕西医学杂志,2021,50(10):1239.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.015]
[10]郑 超,苏 娟,盛杰鑫,等.乳腺癌患者病灶血流时间-信号强度曲线类型、表观弥散系数与化疗疗效相关性分析[J].陕西医学杂志,2021,50(12):1521.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.013]
　ZHENG Chao,SU Juan,SHENG Jiexin,et al.Correlation between focal blood flow time-signal intensity curve type,apparent diffusion coefficient and chemotherapy efficacy in breast cancer patients[J].,2021,50(5):1521.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.013]

备注/Memo

备注/Memo:
[基金项目]甘肃省卫生健康行业科研计划项目(GSWSKY2020-04)
更新日期/Last Update: 2025-05-05